CoChat

Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Abstract

Increased orexin/hypocretin signaling is implicated in opioid withdrawal, sleep disturbances, and drug-seeking behaviors. This study examined whether a dual-orexin receptor antagonist would improve sleep and withdrawal outcomes when compared with placebo during a buprenorphine/naloxone taper. In two-group comparisons, participants receiving suvorexant displayed increased total sleep time (TST) during the buprenorphine/naloxone taper and decreased Subjective Opiate Withdrawal Scale (SOWS) during the post-taper period.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abn8238

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Cited by

See all 79

Metadata

Authors
Huhn, A. S., Finan, P. H., Gamaldo, C. E., Hammond, A. S., Umbricht, A., Bergeria, C. L., Strain, E. C., & Dunn, K. E.
Affiliations
Johns Hopkins University (US)
Corresponding author
Huhn, Andrew S.
Venue
Science Translational Medicine
Published
2022-06-22
Volume
14
Issue
650
Pages
eabn8238-eabn8238
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W4283275984
Cited by
79
References
45
Citations by year
2026: 11 · 2025: 18 · 2024: 28 · 2023: 16 · 2022: 4
FWCI
14.57
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse (UG3DA048734)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
suvorexant, orexin receptor antagonists, opioid use disorder, opioid withdrawal, sleep disorders, total sleep time, opioid craving, abuse liability
MeSH terms
Analgesics, Opioid, Azepines, Buprenorphine, Double-Blind Method, Humans, Naloxone, Narcotic Antagonists, Sleep, Substance Withdrawal Syndrome, Triazoles, Treatment Outcome, Opiate Substitution Treatment, Craving

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.